Tenaya Therapeutics and Alnylam Pharmaceuticals have agreed to collaborate on identifying potential new gene therapies for the treatment of cardiovascular disease. Tenaya will receive an upfront payment of $10 million, but stands to earn much more.
Freestanding EDs demonstrated meaningful operational advantages over hospitals when using an accelerated troponin pathway. This included earlier discharges for low-risk chest pain patients.
The AI model showcased an ability to accurately identify signs of pulmonary hypertension in retinal images. "This opens the possibility of using a simple photograph to gain insights into a premature infant's overall health," one researcher explained.
The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home.
STS plans on using new research out of Mayo Clinic to help with the development of a surgical risk calculator for adults with this challenging condition.
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
Isodose moderately hypofractionated radiotherapy allows patients to undergo just 4-5 weeks of treatment, compared to conventional therapy that can take around 8.
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
